AIDS Research and Treatment / 2013 / Article / Tab 1

Research Article

Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients

Table 1

Baseline characteristics and rate of viral suppression by darunavir dose.

All patientsDRV 1,200 mg dailyDRV 600 mg twice dailyDRV 800 mg daily value

135286542
Age, yr, median (IQR)47 (43–52)48 (42–51)46 (42–51)49 (44–54)0.174
Race/ethnicity0.198
 African American (%)48.160.736.957.1
 Caucasian (%)33.32538.531
 Hispanic (%)1714.321.511.9
 Other/unknown (%)1.503.10
Baseline viral load0.197
 <1,000 copies/mL (%)4345.233.845.2
 1,000–99,999 copies/mL (%)40.740.546.240.5
 ≥100,000 copies/mL (%)16.314.32014.3
 CD4+ cells/mL, mean (SD)343.3399.8 (355.1)259.4 (229.6)435.6 (283.5)0.003
 Concomitant ARVs, mean (SD)2.21.86 (1.01)2.55 (1.00)1.93 (0.71)<0.001
Baseline resistance
 Baseline resistance testing available ( )109/13520/2857/6532/42
 Total DRV RAMs at baseline725661<0.001
 Baseline DRV RAMs, median (range)0 (0–4)0 (0–3)1 (0–4)0 (0-1)<0.001
 Patients with ≥1 documented DRV RAM (%)28.910.753.82.4<0.001
Endpoints
 <50 copies/mL, 24 weeks (%)49.653.652.342.90.568
 <50 copies/mL, 48 weeks (%)48.445.849.248.50.960

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.